Predictive value of homocysteine for depression after acute coronary syndrome
Hee Ju Kang1, Robert Stewart2, Kyung Yeol Bae1
1Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.
Insights
High homocysteine levels are linked to depression in acute coronary syndrome (ACS) patients, especially those with the MTHFR TT genotype. This suggests targeted interventions may reduce depression risk post-ACS.
Area of Science:
- Cardiovascular Medicine
- Psychiatry
- Genetics
Background:
- Depression is a common complication following acute coronary syndrome (ACS).
- Plasma homocysteine and methylenetetrahydrofolate reductase (MTHFR) gene variants are potential risk factors for depression.
- Understanding these factors' roles is crucial for managing depression in ACS patients.
Purpose of the Study:
- To investigate the association between plasma homocysteine, MTHFR genotype, and the risk and persistence of depressive disorder in patients with recent ACS.
- To examine the influence of these factors on antidepressant treatment response.
Main Methods:
- A cohort of 969 patients with recent ACS was recruited, with 711 followed up after 1 year.
- A subset of 378 patients with baseline depressive disorder participated in a 24-week randomized controlled trial of escitalopram versus placebo.
- Plasma homocysteine levels and MTHFR gene polymorphisms (including TT genotype) were assessed.
Main Results:
- Higher plasma homocysteine was independently associated with prevalent depressive disorder at baseline, regardless of MTHFR genotype.
- Elevated homocysteine was linked to incident and persistent depressive disorder at follow-up, but only in patients with the MTHFR TT genotype.
- MTHFR genotype alone was not associated with depressive disorder after ACS.
- No significant associations were found between homocysteine, MTHFR genotype, and antidepressant treatment response over 24 weeks.
Conclusions:
- Plasma homocysteine may serve as a valuable biomarker for depressive disorder, particularly during the acute phase of ACS.
- Interventions targeting individuals with high homocysteine levels and the MTHFR TT genotype could potentially mitigate the risk of developing depression post-ACS.
- Further research is warranted to explore the therapeutic implications of these findings.
Abstract:
We investigated roles of plasma homocysteine and MTHFR gene in relation to risks and treatment responses of depression in ACS. A sample of 969 patients with recent ACS were recruited and 711 followed 1 year later. In addition, of 378 baseline participants with depressive disorder, 255 were randomized to a 24-week double blind trial of escitalopram (N = 127) or placebo (N = 128). A higher homocysteine concentration was independently associated with prevalent depressive disorder at baseline irrespective of MTHFR genotype; and with both incident and persistent depressive disorder at follow-up only in the presence of TT genotype. MTHFR genotype was not itself associated with depressive disorder after ACS. No associations were found with 24-week antidepressant treatment responses. Plasma homocysteine could be a biomarker for depressive disorder particularly in the acute phase of ACS. Focused interventions for those with higher homocysteine level and MTHFR TT genotype might reduce the risk of later depressive disorder.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies
Depressive Disorders: MDD and Dysthymia
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Acute Coronary Syndrome IV: Interprofessional Care
Depression: Overview


